HemaVision

We innovate by using microscopy, artificial intelligence, and robotics to develop cutting-edge technologies for the phenotyping of blood cells and the interpretation of their condition, as well as for the modeling of blood tissue to profile and predict the biological condition of patients and regular individuals in general.

The HemaVision project is based on the industrialization of a pioneering and groundbreaking blood cell membrane labeling system that makes it possible to map the blood with the ultimate goal of increasing life expectancy. Our breakthrough cellular imaging technology offers unprecedented precision and automation that will enable HemaVision to revolutionize the blood circuit in healthcare: from transfusion quality control to clinical diagnosis via AI, Big Data, and robotics.

Need: Firstly, the project addresses the unmet need for donor-recipient matching in blood transfusion: qualitatively matching (adapting) a blood product from the donor to the clinical condition of the recipient, beyond simple immunological compatibility.

Solution: HemaVision's technology uses a unique biochemical marker and innovative imaging techniques to quickly, accurately, and automatically assess the quality of stored blood cells.

Advantages over current methods: Our labeling system offers a faster, more accurate, and more cost-effective method compared to existing processes, which are multi-step, costly, time-consuming, and imprecise.

Market strategy: We are initially targeting cellular imaging platforms to penetrate the market. HemaVision plans to expand to blood banks and research laboratories through analytical solution providers. The project requires €1.5 M, with planned funding phases including regional investors, venture capital, and government grants.

Team: The team includes an expert in biology, an expert in artificial intelligence, and three specialists in software development and cybersecurity, with plans for future recruitment.

Innovation: The project is supported by a patent application for the unique process of blood cell membrane labeling, with additional patents planned for algorithms and imaging systems.

Environment and society: In the first step, the project aims to increase the quality and life expectancy of transfusion patients while reducing side effects, which will lead to a reduction in hospital stays and associated medical waste.

Vision: In the medium term, HemaVision plans to leverage the developed technology to expand into the blood diagnostics market.